1rd4: Difference between revisions

From Proteopedia
Jump to navigationJump to search
OCA (talk | contribs)
No edit summary
OCA (talk | contribs)
No edit summary
Line 4: Line 4:


==Overview==
==Overview==
LFA-1 (lymphocyte function-associated antigen-1) plays a role in, intercellular adhesion and lymphocyte trafficking and activation and is an, attractive anti-inflammatory drug target. The alpha-subunit of LFA-1, in, common with several other integrins, has an N-terminally inserted domain, (I-domain) of approximately 200 amino acids that plays a central role in, regulating ligand binding to LFA-1. An additional region, termed the, I-domain allosteric site (IDAS), has been identified exclusively within, the LFA-1 I-domain and shown to regulate the function of this protein. The, IDAS is occupied by small molecule LFA-1 inhibitors when cocrystallized or, analyzed by (15)N-(1)H HSQC (heteronuclear single-quantum coherence) NMR, (nuclear magnetic resonance) titration experiments. We report here a novel, arylthio inhibitor that binds the I-domain with a K(d) of 18.3 nM as, determined by isothermal titration calorimetry (ITC). This value is in, close agreement with the IC(50) (10.9 nM) derived from a biochemical, competition assay (DELFIA) that measures the level of inhibition of, binding of whole LFA-1 to its ligand, ICAM-1. Having established the, strong affinity of the arylthio inhibitor for the isolated I-domain, we, have used a range of techniques to further characterize the binding, including ITC, NMR, and X-ray crystallography. We have first developed an, effective ITC binding assay for use with low-solubility inhibitors that, avoids the need for ELISA-based assays. In addition, we utilized a fast, NMR-based assay for the generation of I-domain-inhibitor models. This is, based around the collection of HCCH-TOCSY spectra of LFA-1 in the bound, form and the identification of a subset of side chain methyl groups that, give chemical shift changes upon binding of LFA-1 inhibitors. This subset, was used in two-dimensional (13)C-(15)N and (15)N-filtered and -edited, two-dimensional NMR experiments to identify a minimal set of intraligand, and ligand-protein NOEs, respectively (nuclear Overhauser enhancements)., Models from the NMR data were assessed by comparison to an X-ray, crystallographic structure of the complex, confirming that the method, correctly predicted the essential features of the bound ligand.
LFA-1 (lymphocyte function-associated antigen-1) plays a role in intercellular adhesion and lymphocyte trafficking and activation and is an attractive anti-inflammatory drug target. The alpha-subunit of LFA-1, in common with several other integrins, has an N-terminally inserted domain (I-domain) of approximately 200 amino acids that plays a central role in regulating ligand binding to LFA-1. An additional region, termed the I-domain allosteric site (IDAS), has been identified exclusively within the LFA-1 I-domain and shown to regulate the function of this protein. The IDAS is occupied by small molecule LFA-1 inhibitors when cocrystallized or analyzed by (15)N-(1)H HSQC (heteronuclear single-quantum coherence) NMR (nuclear magnetic resonance) titration experiments. We report here a novel arylthio inhibitor that binds the I-domain with a K(d) of 18.3 nM as determined by isothermal titration calorimetry (ITC). This value is in close agreement with the IC(50) (10.9 nM) derived from a biochemical competition assay (DELFIA) that measures the level of inhibition of binding of whole LFA-1 to its ligand, ICAM-1. Having established the strong affinity of the arylthio inhibitor for the isolated I-domain, we have used a range of techniques to further characterize the binding, including ITC, NMR, and X-ray crystallography. We have first developed an effective ITC binding assay for use with low-solubility inhibitors that avoids the need for ELISA-based assays. In addition, we utilized a fast NMR-based assay for the generation of I-domain-inhibitor models. This is based around the collection of HCCH-TOCSY spectra of LFA-1 in the bound form and the identification of a subset of side chain methyl groups that give chemical shift changes upon binding of LFA-1 inhibitors. This subset was used in two-dimensional (13)C-(15)N and (15)N-filtered and -edited two-dimensional NMR experiments to identify a minimal set of intraligand and ligand-protein NOEs, respectively (nuclear Overhauser enhancements). Models from the NMR data were assessed by comparison to an X-ray crystallographic structure of the complex, confirming that the method correctly predicted the essential features of the bound ligand.


==About this Structure==
==About this Structure==
Line 14: Line 14:
[[Category: Single protein]]
[[Category: Single protein]]
[[Category: Alexander, R.]]
[[Category: Alexander, R.]]
[[Category: Archibald, S.C.]]
[[Category: Archibald, S C.]]
[[Category: Ceska, T.A.]]
[[Category: Ceska, T A.]]
[[Category: Connell, J.O.]]
[[Category: Connell, J O.]]
[[Category: Crump, M.P.]]
[[Category: Crump, M P.]]
[[Category: Findlow, S.C.]]
[[Category: Findlow, S C.]]
[[Category: Henry, A.]]
[[Category: Henry, A.]]
[[Category: Robinson, M.K.]]
[[Category: Robinson, M K.]]
[[Category: Shock, A.]]
[[Category: Shock, A.]]
[[Category: Spyracopoulos, L.]]
[[Category: Spyracopoulos, L.]]
[[Category: Taylor, R.J.]]
[[Category: Taylor, R J.]]
[[Category: L08]]
[[Category: L08]]
[[Category: immune system]]
[[Category: immune system]]


''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Fri Feb 15 16:48:12 2008''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 14:49:34 2008''